Researchers from the European Centre for Allergy Research Foundation (ECARF) and the Institute of Allergology at Charité Universitätsmedizin Berlin have conducted clinical trials on Respiray Wear A+, revealing that the wearable allergy relief device reduced the symptoms of pollen, dust mite and cat allergies more effectively than most anti-allergy medications or allergen-specific immunotherapy.
Full Article
MONDAY, April 22, 2024 (HealthDay News) -- Two common PFAS "forever chemicals" have been deemed hazardous substances by the Environmental Protection Agency.